+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bi-Specific MAbS Global Market Report 2022

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553759
Bi-Specific MAbS Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global bi-specific mabs market.



This report focuses on bi-specific mabs market which is experiencing strong growth. The report gives a guide to the bi-specific mabs market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the bi-specific mabs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Bi-Specific MAbS market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider bi-specific mabs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The bi-specific mabs market section of the report gives context. It compares the bi-specific mabs market with other segments of the bi-specific mabs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, bi-specific mabs indicators comparison

Scope


Markets Covered:


1)By Type: Catumaxomab (Removab); Blinatumomab; Duligotumab; SAR 156597
2)By Product Type: In Vivo; In Vitro
3)By Indication: Cancer; Autoimmune Diseases; Inflammatory Diseases; Infectious Diseases; Microbial Diseases; Others
4)By End Use: Hospitals; Research Institutes; Others

Companies Mentioned:Johnson & Johnson; Novartis AG; Hoffmann-La Roche Ltd; Novo Nordisk A/S; Bayer AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Bi-Specific Mabs Market

What is the estimated value of the Global Bi-Specific Mabs Market?

The Global Bi-Specific Mabs Market was estimated to be valued at $5.1 billion in 2022.

What is the growth rate of the Global Bi-Specific Mabs Market?

The growth rate of the Global Bi-Specific Mabs Market is 22.7%, with an estimated value of $11.6 billion by 2026.

What is the forecasted size of the Global Bi-Specific Mabs Market?

The Global Bi-Specific Mabs Market is estimated to be worth $11.6 billion by 2026.

Who are the key companies in the Global Bi-Specific Mabs Market?

Key companies in the Global Bi-Specific Mabs Market include Johnson & Johnson, Novartis AG, Hoffmann, La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, inc., Bistro and Daiichi Sankyo Company, Ltd..

Table of Contents

1. Executive Summary2. Bi-Specific MAbS Market Characteristics3. Bi-Specific MAbS Market Trends And Strategies4. Impact Of COVID-19 On Bi-Specific MAbS
5. Bi-Specific MAbS Market Size And Growth
5.1. Global Bi-Specific MAbS Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Bi-Specific MAbS Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Bi-Specific MAbS Market Segmentation
6.1. Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Catumaxomab (Removab)
  • Blinatumomab
  • Duligotumab
  • SAR 156597
6.2. Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • In Vivo
  • In Vitro
6.3. Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Microbial Diseases
  • Others
6.4. Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals
  • Research Institutes

7. Bi-Specific MAbS Market Regional And Country Analysis
7.1. Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Bi-Specific MAbS Market
8.1. Asia-Pacific Bi-Specific MAbS Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Bi-Specific MAbS Market
9.1. China Bi-Specific MAbS Market Overview
9.2. China Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Bi-Specific MAbS Market
10.1. India Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Bi-Specific MAbS Market
11.1. Japan Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Bi-Specific MAbS Market
12.1. Australia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Bi-Specific MAbS Market
13.1. Indonesia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Bi-Specific MAbS Market
14.1. South Korea Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Bi-Specific MAbS Market
15.1. Western Europe Bi-Specific MAbS Market Overview
15.2. Western Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Bi-Specific MAbS Market
16.1. UK Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Bi-Specific MAbS Market
17.1. Germany Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Bi-Specific MAbS Market
18.4. France Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Bi-Specific MAbS Market
19.1. Eastern Europe Bi-Specific MAbS Market Overview
19.2. Eastern Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Bi-Specific MAbS Market
20.1. Russia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Bi-Specific MAbS Market
21.1. North America Bi-Specific MAbS Market Overview
21.2. North America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Bi-Specific MAbS Market
22.1. USA Bi-Specific MAbS Market Overview
22.2. USA Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Bi-Specific MAbS Market
23.1. South America Bi-Specific MAbS Market Overview
23.2. South America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Bi-Specific MAbS Market
24.1. Brazil Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Bi-Specific MAbS Market
25.1. Middle East Bi-Specific MAbS Market Overview
25.2. Middle East Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Bi-Specific MAbS Market
26.1. Africa Bi-Specific MAbS Market Overview
26.2. Africa Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Bi-Specific MAbS Market Competitive Landscape And Company Profiles
27.1. Bi-Specific MAbS Market Competitive Landscape
27.2. Bi-Specific MAbS Market Company Profiles
27.2.1. Johnson & Johnson
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Novartis AG
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Hoffmann-La Roche Ltd.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Novo Nordisk A/S
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Bayer AG
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Bi-Specific MAbS Pipeline Analysis29. Key Mergers And Acquisitions In The Bi-Specific MAbS Market30. Bi-Specific MAbS Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott.

The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

The main types of bi-specific are catumaxomab (removab), blinatumomab, duligotumab, SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types include in vivo, in vitro that are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales, and hence impacting the bi-specific MAbS market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market in the near future.

Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.

In August 2020, AbCellera , a biotechnology firm based in Canada, completed the acquisition of OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics.

The countries covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Johnson & Johnson
  • Novartis AG
  • Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Bayer AG
  • Thermo Fisher Scientific, inc.
  • Bistro-Myers Squibb. Mylan N.V.
  • Daiichi Sankyo Company, Ltd.
  • Abbott
  • AstraZeneca
  • Eli Lilly
  • Merck & Co. inc.
  • Amgen inc.
  • Pfizer inc.
  • GlaxoSmithKline plc.
  • Roche
  • Sanofi
  • Genentech
  • Immunomedics
  • Chugai Pharmaceutical
  • EMD Serono
  • Emergent BioSolutions
  • Jounce Therapeutics
  • MarcoGenics
  • Merus
  • Neovii Biotech
  • NovImmune SA
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals

Methodology

Loading
LOADING...